PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC 50 of 2.3 nM in vivo In Vivo PFE-360 (4 mg/kg and 7.5 mg/kg, orally, BID, 10-12 weeks) treatment potently decreases the LRRK2-pSer935/total LRRK2 ratio, with no significant adverse effects . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Sprague Dawley rats (NTac:SD) weighed 225-250 g. Dosage: 4 mg/kg and 7.5 mg/kg ( pharmacokinetics and pharmacodynamics ). Administration: Orally BID for 10-12 weeks. Result: The LRRK2-pSer935/total LRRK2 ratio was significantly decreased at both 1 h and 12 h after dosing. The terminal bodyweights exhibited no significant changes. Form:Solid IC50& Target:IC50: 2.3 nM (LRRK2 in vivo)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
PFE-360
CAS number：1527475-61-1 molecular formula：C16H16N6O
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1527475-61-1 | molecular formula | C16H16N6O |
| molecular weight | 308.34 g/mol | Exact mass | ≥98% |
| PSA | 82.800 Ų | logp | 1.200 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
